|Study Of The Safety And Efficacy Of Lyrica In The Treatment Of Newly Diagnosed Partial Epilepsy|
|A Randomized, Comparative, Double-Blind, Parallel-Group, Multicenter, Monotherapy, Study Of Pregabalin (Lyrica) And Lamotrigine (Lamictal) In Patients With Newly Diagnosed Partial Seizures|
|The purpose of this study is to assess whether Lyrica is a safe and effective treatment for partial epilepsy in comparison with an established treatment, Lamictal.|
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
|Kwan P, Brodie MJ, Kälviäinen R, Yurkewicz L, Weaver J, Knapp LE. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol. 2011 Oct;10(10):881-90. doi: 10.1016/S1474-4422(11)70154-5. Epub 2011 Aug 31.|
|December 2009 (Final data collection date for primary outcome measure)|
- Patients must be diagnosed with partial epilepsy and have experienced at least 2 partial seizures (simple partial, complex partial or partial seizure with secondary generalization) in the past year with one in the past 6 months.
- Treatable causes of seizures, for example identified etiologies including metabolic, neoplastic or active infectious origin.
- Primary generalized seizures.
|Sexes Eligible for Study:||All|
|16 Years and older (Child, Adult, Older Adult)|
|Contact information is only displayed when the study is recruiting subjects|
|Belgium, Bulgaria, China, Colombia, Czech Republic, Estonia, Finland, France, Germany, Hong Kong, Hungary, India, Ireland, Italy, Korea, Republic of, Latvia, Lithuania, Mexico, Netherlands, Norway, Portugal, Romania, Singapore, Slovakia, Spain, Sweden, Taiwan, Thailand, United Kingdom|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|